Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 8/20 | 0.37 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941413 | 0.91 | HDAC11 (0.41) | FGFR1RETAURKAAURKBPTGES | |
| SCHEMBL938739 | 0.91 | HDAC11 (0.36) | FGFR1RETAURKAAURKBPTGES | |
| SCHEMBL939150 | 0.91 | CSNK1E (0.35) | CSNK1ECSNK1G3FGFR1RETPTGES | |
| SCHEMBL940006 | 0.89 | HDAC11 (0.39) | FGFR1RETAURKAAURKBPTGES | |
| SCHEMBL941048 | 0.88 | FGFR1 (0.39) | FGFR1RETAURKAAURKBPTGES | |
| SCHEMBL940266 | 0.88 | PTGES (0.38) | FGFR1RETAURKAAURKBPTGES | |
| SCHEMBL939309 | 0.86 | AURKB (0.38) | FGFR1RETAURKAAURKBMARK3 | |
| SCHEMBL940838 | 0.86 | PTGES (0.36) | CSNK1EFGFR1RETAURKAAURKB | |
| SCHEMBL939855 | 0.86 | FGFR1 (0.46) | FGFR1RETAURKAAURKBHDAC11 | |
| SCHEMBL939356 | 0.86 | POLB (0.43) | FGFR1RETAURKAAURKBPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | claimed |
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | claimed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | CSNK1E 431/4885CSNK1G3 312/4885FGFR1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.